Dr. Ranjith B. Dissanayake, MD

Dr. Dissanayake practices at Ascension Sacred Heart Pensacola in Pensacola, Florida, part of Ascension Health Alliance.

Dr. Dissanayake's NPI, 1861475170, was assigned on November 22, 2005. Dr. Dissanayake graduated from University of Peradeniya FOM in 1991. Dr. Dissanayake holds Florida license ME0086035.

Dr. Dissanayake's primary practice is Ascension Sacred Heart Pensacola, at 5151 N 9th Ave, Pensacola, FL 32504 in Escambia County. The practice phone is (850) 416-7000.

Dr. Dissanayake's primary practice is Ascension Sacred Heart Pensacola in Pensacola, Florida, part of Ascension Health Alliance. Dr. Dissanayake is also affiliated with Baptist Hospital. The medical group on file is Sacred Heart Medical Group. Dmand AI also links Dr. Dissanayake to 1 more hospital, 1 clinical lab and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dissanayake practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dissanayake's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dissanayake is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Dissanayake's licenses on file in 2 states: Florida and Illinois.

Dmand AI lists anemia, breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT) and fluid and electrolyte imbalances among the conditions Dr. Dissanayake treats.

CMS data shows 1,728 Medicare services from Dr. Dissanayake across 9 procedure codes in 2024, for 552 Medicare patients. Medicare paid $108,410 for them.

CMS counts 552 Medicare patients who saw Dr. Dissanayake in 2024. The largest group is 75 to 84, with 224 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dissanayake's median patient age at 72, with 62% women.

In 2024, Dr. Dissanayake wrote 1,074 Medicare Part D claims for 231 patients. 73% of them were for generic drugs. CMS names the drug for 828 of them, across 29 drugs with 11 or more claims each, at $2,884,694 in total drug cost. In 2023, CMS named 811 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Dissanayake for performance year 2024, reported through an alternative payment model (APM). Dr. Dissanayake accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Dissanayake.

Dmand AI links Dr. Dissanayake to 11 clinical trials, 9 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 74 general payments to Dr. Dissanayake from 22 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Celgene Corporation paid the most, $378.

Dr. Dissanayake graduated from University of Peradeniya FOM in 1991.

Dr. Dissanayake is in network with 15 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.